The effect of caffeine on estimates of persistent inward currents in human motor units

Not Applicable

Completed

• Conditions: Exercise performance after caffeine consumption; Neurotransmitter level imbalance; Musculoskeletal - Normal musculoskeletal and cartilage development and function; Neurological - Studies of the normal brain and nervous system; Metabolic and Endocrine - Normal metabolism and endocrine development and function

• Registration Number: ACTRN12621001665820
• Lead Sponsor: Karen Mackay

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-09-07
• Study Start: 2021-12-03
• Last Update Posted: 13 December 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

Healthy non-smokers , BMI <30 kg/m2

Exclusion Criteria

Musculoskeletal disorders that limit performance in the assessed limb; diagnosed neurological disorders (e.g. amyotrophic lateral sclerosis or ALS); diagnosed serotonergic disorders (e.g. depression); consumption of drugs that affect serotonin and noradrenaline release (e.g. recreational drugs such as marihuana and ecstasy, SRRIs or antidepressants); Women must not be pregnant, breast feeding or menopausal.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Estimates of persistent inward currents (PICs): Measured using high density electromyopgraphy (EMG) placed on the tibialis anterior muscle (front leg), while sitting on a leg dynamometer.[At baseline and 60 mins after consumption of capsules (on each visit)];Time to muscle fatigue (TTF): Measured on a leg dynamometer.[90 min after consumption of the capsules (on each visit).]

Secondary Outcome Measures

Name	Time	Method
Maximal voluntary contraction (MVC): Measured on a leg dynamometer.[At baseline and 60 mins after consumption of capsules (on each visit)];Rate of force development (RFD): Measured on a leg dynamometer.[At baseline and 60 mins after consumption of capsules (on each visit)]